Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP] (Q83426841)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

Christian Savard

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Marie-Ève Laliberté-Gagné

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Cindy Babin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Marilène Bolduc

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Annie Guérin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Karine Drouin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Marie-Andrée Forget

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Nathalie Majeau

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Réjean Lapointe

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Denis Leclerc

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

8 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

2535-2542

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

Development of a vaccine against pandemic influenza viruses: current status and perspectives.

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Efficacy and effectiveness of influenza vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Correlates of protection: novel generations of influenza vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Control of influenza virus infection by immunity to conserved viral features.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Biological and genetic evolution of the nucleoprotein gene of human influenza A viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Analysis of influenza A virus nucleoproteins for the assessment of molecular genetic mechanisms leading to new phylogenetic virus lineages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

The influenza A virus nucleoprotein gene controls the induction of both subtype specific and cross-reactive cytotoxic T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Recognition of influenza A virus nucleoprotein by human cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Selective expansion of cross-reactive CD8(+) memory T cells by viral variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

CD4+ and CD8+ mediated cellular immune response to recombinant influenza nucleoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

"Peptabody": a new type of high avidity binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

High avidity binding of engineered papaya mosaic virus virus-like particles to resting spores of Plasmodiophora brassicae

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Label-free detection of biomolecular interactions in real time with a nano-porous silicon-based detection method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces CD8 T-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Purified influenza virus nucleoprotein protects mice from lethal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Vaccine adjuvants revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Virus-like particles: passport to immune recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

The influence of antigen organization on B cell responsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

IgG2a restriction of murine antibodies elicited by viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Rectification of age-associated deficiency in cytotoxic T cell response to influenza A virus by immunization with immune complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Characterization and Immunological Properties of Influenza A Virus Nucleoprotein (NP): Cell-associated NP Isolated from Infected Cells or Viral NP Expressed by Vaccinia Recombinant Virus do not Confer Protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

INDUCTION OF PARTIAL SPECIFIC HETEROTYPIC IMMUNITY IN MICE BY A SINGLE INFECTION WITH INFLUENZA A VIRUS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

7 January 2021

Evolution of the nucleoprotein gene of influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

7 January 2021

Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

7 January 2021

Immunization of pigs with a particle-mediated DNA vaccine to influenza A virus protects against challenge with homologous virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.01.085

7 January 2021

10.1016/J.VACCINE.2012.01.085

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22326774%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference